A detailed history of Virtus ETF Advisers LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 3,741 shares of AKRO stock, worth $109,760. This represents 0.05% of its overall portfolio holdings.

Number of Shares
3,741
Previous 3,677 1.74%
Holding current value
$109,760
Previous $86,000 24.42%
% of portfolio
0.05%
Previous 0.04%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.45 - $29.34 $1,372 - $1,877
64 Added 1.74%
3,741 $107,000
Q2 2024

Aug 14, 2024

SELL
$18.31 - $24.62 $3,698 - $4,973
-202 Reduced 5.21%
3,677 $86,000
Q1 2024

May 15, 2024

SELL
$17.76 - $31.18 $4,777 - $8,387
-269 Reduced 6.49%
3,879 $97,000
Q4 2023

Feb 15, 2024

BUY
$11.38 - $50.33 $26,777 - $118,426
2,353 Added 131.09%
4,148 $96,000
Q3 2023

Nov 07, 2023

SELL
$41.19 - $52.25 $7,249 - $9,196
-176 Reduced 8.93%
1,795 $90,000
Q2 2023

Aug 14, 2023

SELL
$36.89 - $56.88 $11,731 - $18,087
-318 Reduced 13.89%
1,971 $92,000
Q1 2023

May 15, 2023

SELL
$37.27 - $50.24 $32,611 - $43,960
-875 Reduced 27.65%
2,289 $87,000
Q4 2022

Feb 14, 2023

SELL
$33.44 - $54.8 $328,280 - $537,971
-9,817 Reduced 75.63%
3,164 $173,000
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $1,004 - $3,370
99 Added 0.77%
12,981 $442,000
Q2 2022

Aug 12, 2022

BUY
$8.0 - $15.01 $40,640 - $76,250
5,080 Added 65.11%
12,882 $122,000
Q1 2022

May 16, 2022

SELL
$12.97 - $22.26 $6,018 - $10,328
-464 Reduced 5.61%
7,802 $111,000
Q4 2021

Feb 14, 2022

BUY
$19.87 - $26.24 $22,254 - $29,388
1,120 Added 15.67%
8,266 $175,000
Q3 2021

Nov 15, 2021

SELL
$18.65 - $25.46 $7,086 - $9,674
-380 Reduced 5.05%
7,146 $160,000
Q2 2021

Aug 10, 2021

SELL
$24.81 - $32.35 $72,643 - $94,720
-2,928 Reduced 28.01%
7,526 $187,000
Q1 2021

May 17, 2021

BUY
$24.04 - $34.19 $4,279 - $6,085
178 Added 1.73%
10,454 $303,000
Q4 2020

Feb 12, 2021

SELL
$25.12 - $29.89 $60,539 - $72,034
-2,410 Reduced 19.0%
10,276 $265,000
Q3 2020

Nov 13, 2020

SELL
$30.79 - $39.92 $53,543 - $69,420
-1,739 Reduced 12.06%
12,686 $391,000
Q2 2020

Aug 05, 2020

SELL
$19.25 - $26.76 $50,666 - $70,432
-2,632 Reduced 15.43%
14,425 $359,000
Q1 2020

May 14, 2020

SELL
$12.8 - $27.05 $31,667 - $66,921
-2,474 Reduced 12.67%
17,057 $362,000
Q4 2019

Feb 13, 2020

BUY
$17.37 - $27.27 $339,253 - $532,610
19,531 New
19,531 $433,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.36B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.